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Abstract
Background: The epidemiology of osteomyelitis in Germany is unknown, which makes it difficult to estimate future
demands. Therefore, we aimed to analyse how the numbers of cases have developed over the last decade as a
function of osteomyelitis subtype, age group, gender, and anatomical localization.
Methods: Osteomyelitis rates were quantified based on annual ICD-10 diagnosis codes from German medical
institutions between 2008 through 2018, provided by the Federal Statistical Office of Germany (Destatis).
Results: Overall osteomyelitis prevalence increased by 10.44% from 15.5 to 16.7 cases per 100,000 inhabitants
between 2008 through 2018. Out of 11,340 cases in 2018, 47.6% were diagnosed as chronic, 33.2% as acute and
19.2% as unspecified osteomyelitis. Men were often affected than women with 63.4% of all cases compared to
36.6%. The largest proportion of patients comprised the age group 60–69 years (22.1%), followed by 70–79 years
(21.7%). A trend towards more osteomyelitis diagnoses in older patients was observed. Lower extremities were
most frequently infected with 73.8% of all cases in 2018 (+ 10.8% change).
Conclusions: Osteomyelitis remains a serious problem for orthopedic and trauma surgery. Prevention methods and
interdisciplinary approaches are strongly required.
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Background
Osteomyelitis has accompanied mankind from its very
beginning and still remains a difficult to manage challenge
in orthopaedic and trauma surgery [1]. Osteomyelitis can
occur to a variety of reasons. Hematogenous infection is
possible as well as direct inoculation of bacteria to bone,
which occurs in open fractures, after surgery or skin
breakdown secondary to vascular insufficiency or per-
ipheral neuropathy [2]. Several classifications for osteo-
myelitis exist such as the one introduced by Waldvogel
and colleagues or George Cierny and John Mader. The
former includes a temporal distinction between acute
and chronic, which is important for the treatment strat-
egy [2, 3]. In acute osteomyelitis, defined by symptoms
less than 2 weeks, empirical antibiotic long-term ther-
apy is feasible since establishment of a mature biofilm
might not have taken place, which is the hallmark of
chronic osteomyelitis. Once formation of biofilm is
accomplished, susceptibility to antibiotic therapy is sig-
nificantly reduced and eradication of infection without
surgical treatment is not possible [3].
While there was no curative therapy until modern
times, advances in modern medicine have led to the fact
that at least osteomyelitis is no longer associated with an
almost inevitable death. Milestones for a curative treat-
ment are the development of surgical treatment concepts
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which focus on infect eradication followed by bone defect
reconstruction. The discovery of penicillin and further de-
velopment of an array of different antibiotics, the use of
local antibiotic carriers as well as surgical procedures such
as bone transfer introduced by Ilizarov, Masquelet’s mem-
brane induced technique or free flap surgery invented by
Harry J Buncke contributed to the progress in orthopaedic
and trauma surgery [4–7]. Although joint replacement
procedures and surgical fracture treatment with internal
fixation devices have become an integral part of modern
medicine enhancing patients’ quality of life, they represent
an additional risk of bone and joint infection. For instance,
rates of developing a posttraumatic infection are reported
to be around 1–2% for closed fractures ranging up to ex-
ceeding 30% for Gustilo-Anderson type III open tibia
fractures despite prevention strategies [8–11]. Depending
on injury severity, success rates only vary between 70 and
90% with a recurrence of the disease in 6–9% of the pa-
tients [12–14]. Healthcare costs of fracture-related infec-
tions were estimated to be approximately 6.5 times higher
than in non-infected cases [15]. As incidences of long
bone fractures increase, projected numbers of infection
complications are expected to rise as well [16]. Addition-
ally, the global prevalence of diabetes is projected to in-
crease up to 7079 individuals per 100,000 by 2030 [17],
hence also heightening the risk of osteomyelitis.
To estimate future demands for this potentially com-
ing challenge and to foresee developments which could
be influenced by adaption of prevention and therapeutic
measures, analysis of trends in osteomyelitis rates are
required. However, no analysis of the epidemiology of
osteomyelitis for European countries is available.
We have therefore aimed to answer the following
questions: (1) How have the numbers of cases developed
over the last decade as a function of osteomyelitis sub-
type and localization? (2) How does age and gender
influence the numbers in the observation period?
Methods
Data consisting of annual ICD-10 diagnosis codes, which
were implemented in Germany in January 2000, from
German medical institutions between 2008 to 2018 was
provided by the Federal Statistical Office of Germany
(Destatis). The dataset included only patients who re-
ceived inpatient treatment. The ICD-10 code “M86.-”
was used to identify patients aged 20 years or older
diagnosed with osteomyelitis. A detailed breakdown of
these data by age group, gender, type of osteomyelitis
and anatomical localization was performed. In particular,
for composing the subgroup “acute osteomyelitis, the
ICD-10 codes “M86.0, M86.1, M86.2” were used,
whereas chronic osteomyelitis was determined by the
codes “M86.3, M86.4, M86.5, M86.6” and unspecified
osteomyelitis by “M86.8, M86.9″. Localization was
retrieved by using the codes “-1, shoulder”, “-2, humerus”,
“-3, radius and ulna”, and “-4, hand” to compile the upper
extremity subgroup and “-5, femur”, “-6, tibia and fibula”
and “-7, ankle and foot” for the lower extremity subgroup,
respectively. Prevalence rates were calculated based on
Germany’s historical population aged 20 years or older
provided by Destatis [18]. Here, the number of inhabitants
in each of the 16 German federal states was considered by
year of birth for each year of the period 2008 to 2018. The
deadline of each year was December 31. Data were
analyzed using the statistical software SPSS Version 26.0
(IBM, SPSS Inc. Armonk, NY, USA).
Results
In 2018, a total number of 11,340 osteomyelitis cases in
Germany was reported. In comparison to 10,268 cases in
2008, the overall prevalence increased by 10.44% from
15.5 cases per 100,000 inhabitants to 16.7 cases per 100,
000 inhabitants. Between 2008 through 2012 total num-
bers decreased and subsequently rose again with a max-
imum of cases in the year 2016. (Table 1). The largest
proportion of osteomyelitis cases in 2018 comprised
chronic cases (47.6%), followed by 33.2% acute cases and
19.2% unspecified cases. The total number of cases diag-
nosed with acute osteomyelitis increased by 61.8% from
2327 to 3765 between 2008 and 2018. An increasing
trend could also be observed regarding chronic osteo-
myelitis cases, which heightened by 8.4% from 4984 to
5402 cases in total between 2008 and 2018, whereas
osteomyelitis cases classified as unspecified decreased by
26.5% from 2957 to 2173 patients (Table 2).
Overall, men were more often affected than women,
whereby the proportion of male cases increased from
61.4 to 63.4% and female cases decreased from 38.6 to
36.6% accordingly (Fig. 1, Table 3). Patients aged 60–69
Table 1 Historic development of population and osteomyelitis










2008 10,268 66,346,045 15.5
2009 9932 −3.27 66,400,066 15.0
2010 9893 −3.65 66,549,975 14.9
2011 10,053 −2.09 65,398,514 15.4
2012 10,107 −1.57 65,665,069 15.4
2013 10,452 + 1.79 65,943,867 15.8
2014 10,351 + 0.81 66,677,665 15.5
2015 10,860 + 5.77 67,097,676 16.2
2016 11,480 + 11.8 67,440,230 17.0
2017 11,331 + 10.35 67,540,025 16.8
2018 11,340 + 10.44 67,724,921 16.7
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2008 2327 (22.7) 4984 (48.5) 2957 (28.8)
2009 2292 (23.1) 4748 (47.8) 2892 (29.1)
2010 2306 (23.3) 4848 (49.0) 2739 (27.7)
2011 2444 (24.3) 4997 (49.7) 2612 (26.0)
2012 2480 (24.5) 4914 (48.6) 2713 (26.8)
2013 2644 (25.3) 4983 (47.7) 2825 (27.0)
2014 2636 (25.5) 4988 (48.2) 2727 (26.3)
2015 2799 (25.8) 5347 (49.2) 2714 (25.0)
2016 3414 (29.7) 5720 (49.8) 2346 (20.4)
2017 3621 (32.0) 5446 (48.1) 2264 (20.0)
2018 3765 (33.2) 5402 (47.6) 2173 (19.2)
Fig. 1 Development of osteomyelitis diagnoses as a factor of gender. a Shows the amount of total cases per year. Male cases are shown in dark
grey, female cases in light grey. b The prevalence per 100,000 male inhabitants is shown in dark grey, prevalence per 100,000 female inhabitants
is illustrated in light grey
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years comprised the largest cohort with 22.1%, followed
by patients aged 70–79 years (21.7%) and patients aged
50–59 years (20.3%). Relative to the year 2008, a trend
towards more osteomyelitis diagnoses in older patients
can be observed. The largest increase was found in the
population aged 90 years or older (+ 115.2% change). In
the increment 80–89 years 37.8% more cases were regis-
tered and 13.0% more patients in the age between 70
and 79 years were affected. Also, the prevalence height-
ened in patients aged 60–69 years (+ 11.9% change) and
in patients aged 50–59 years (+ 18.4% change). Accord-
ingly, less patients aged 40–49 years were diagnosed with
osteomyelitis (− 22.1% change) and numbers decreased
in the age group 30–39 years (− 5.9% change) as well as
20–29 years (− 15.4% change) (Fig. 2, Table 3). The most
frequently infected region was the lower extremity with
73.8% of all cases in 2018, whereby numbers rose by
10.8% from 7553 cases in 2008 to 8371 cases in 2018.
Osteomyelitis occurred in 17.7% of all cases at the upper
extremity, with an increase of 32.14% from 1515 cases in
2008 to 2002 cases in 2018. Other regions were involved
in 8.5% of all cases, with decreasing prevalence of 19.4%
from 1200 cases in 2008 to 967 cases in 2018 (Fig. 3,
Fig. 4, Table 3).
Discussion
In this population-based study trends in the epidemi-
ology of osteomyelitis were described and prevalence
was analyzed as a function of osteomyelitis subtype, ana-
tomical localization, gender, and age group. Some litera-
ture provides insights regarding selected subgroups or
subtypes of osteomyelitis, such as pediatric patients [19,
20] or vertebral osteomyelitis [21]. Additionally, the epi-
demiology of osteomyelitis has been analyzed based on a
survey of residents of Olmsted County, Minnesota,
United States, reporting 760 cases [22]. However, there
Fig. 2 Development of osteomyelitis numbers as a factor of age groups in 10-year increments. a Total number of osteomyelitis diagnoses, (b)
age standardized prevalence per 100,000 inhabitants
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is a lack of data estimating the prevalence of osteomye-
litis for European countries. This study, to the best of
our knowledge, is the first one describing the nationwide
burden of osteomyelitis.
It was demonstrated that the number of cases in-
creased by 10.44% over the last decade up to 16.7 per
100,000 inhabitants in 2018. In the light of a recent
study calculating annual numbers of revision total knee
arthroplasty procedures associated with periprosthetic
joint infection (PJI) as 30.8 per 100,000 German inhabi-
tants in 2018, forecasting an increase of almost 90% in
2050 [23], the dynamic in total osteomyelitis numbers
seem surprisingly low. Here, the importance of delimitation
between osteomyelitis and PJI becomes evident. Whereas
the lines between the two diagnoses often appear to be
blurred in literature [24–26], strictly applying the definition
criteria of the European Bone and Joint Infection Society
(EBJIS) [27] excludes PJI from the category ‘bone infection’.
Further, PJI is distinctly coded according to the ICD-10 as
“T84.5, infection and inflammatory reaction by a joint
endoprosthesis” and therefore, not included in our analysis.
Also, the prevalence rates in Germany were lower in com-
parison to 24.4 incident cases of osteomyelitis per 100,000
person-years estimated for the U. S [22], which might be
Fig. 4 Acute and chronic osteomyelitis cases for the upper and lower extremity, respectively
Fig. 3 Development of osteomyelitis numbers as a factor of anatomical localization
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explainable by differences in methodology. For instance, we
did not consider vertebral osteomyelitis as spondylodiscitis
is coded separately.
Our analysis also revealed that men were often af-
fected than women, which is in accordance with findings
by Kremers and colleagues reporting significantly lower
incidences of 16.7 cases per 100,000 person-years for
women compared to 27.7/100,000 for men [22].
Whereas underlying mechanisms are not fully under-
stood yet, research increasingly addresses the import-
ance of sex differences in immune response [28, 29].
The observed trend towards more osteomyelitis diagno-
sis in older patients possibly reflects demographic
changes such as population decline and aging, which
challenge the healthcare system not only in Germany.
Further, higher numbers of chronic cases compared to
acute cases were determined, whereas the prevalence of
acute osteomyelitis rose by 61.8%. This finding may be
attributable to recent advances in prevention strategies,
early diagnosis of low-grade infections or awareness
to discriminate acute and chronic bone infections [11,
30, 31]. However, potential biases in the distinction
between acute and chronic osteomyelitis might influ-
ence these numbers as different definitions exits in
the literature [32].
Our study is limited by the fact, that, although ICD-10
codes were available, it was not possible to differentiate
possible driving comorbid factors, such as diabetes melli-
tus, peripheral vascular disease, trauma or the implant-
ation of medical devices. Additionally, the analysed
dataset did not include information regarding treatment
procedure. Further, no statement regarding the distribu-
tion of pathogens causing the infection can be made.
Also, we assumed correct diagnosing based on published
criteria [31], however, a possible upcoding cannot be
excluded.
Conclusions
Osteomyelitis remains a serious problem for orthopedic
and trauma surgery, also for countries comparable with
Germany. In light of a strong increase especially in eld-
erly patients, prevention strategies, improved treatment
strategies and an interdisciplinary treatment approach
are required.
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